A study published in Cell Death Discovery reports that blocking PHGDH can overcome resistance to dabrafenib in BRAF V600E anaplastic thyroid carcinoma by driving metabolic rewiring. The work by researchers including S.Y. Kim and M.H. You identifies PHGDH as a metabolic vulnerability that may be exploitable in patients whose tumors adapt to BRAF inhibition.